REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD

Key Takeaways Regeneron won EC nod to expand Libtayo as adjuvant therapy for high-risk CSCC after surgery and radiation.FDA approved Eylea HD for RVO with dosing up to every eight weeks after an initial monthly period.The agency also cleared a monthly option of Eylea HD across wAMD, DME, DR and RVO for select patients.Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission (EC) has approved label expansion of its PD-1 inhibitor Libtayo (cemiplimab).The EC approved Libtayo as an adjuvan ...